FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:1781-1784 April 23, 2009 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Jones, R. H. PubMed Citation

Congestive heart failure is one of the leading causes of death and complications in the developed world, and coronary artery disease is the major cause of heart failure. Efforts to improve ventricular function, symptoms, and clinical outcomes in patients with heart failure have included neurohormonal inhibition with angiotensin-converting–enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, and aldosterone antagonists, as well as cardiac resynchronization therapy. All these therapies have been shown in randomized clinical trials to be beneficial.¹ However, none of them specifically address the coronary disease responsible for ischemic cardiomyopathy and myocardial infarction.

Coronary-artery bypass grafting (CABG), which was first used to ameliorate . . . [Full Text of this Article]

Source Information

From the Division of Cardiology, Drexel University College of Medicine, Philadelphia.

This article (10.1056/NEJMe0901815) was published at NEJM.org on March 29, 2009.

This article has been cited by other articles:

• Maurer, G. (2009). Mitral Leaflet in Functional Regurgitation: Passive Bystander or Active Player?. Circulation 120: 275-277 [Full Text]